Business Context and Reporting Period
Company: AnaptysBio, Inc. (ANAB)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: AnaptysBio is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. The company operates two distinct segments: a Biopharma segment developing wholly-owned assets (rosnilimab, ANB033, ANB101) and a Royalty Management segment managing financial collaborations for Jemperli (with GSK) and imsidolimab (with Vanda).
Strategic Development: In September 2025, the Board approved plans to separate the business into two independent, publicly traded companies, expected to be completed in Q2 2026.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $234.6 million | $91.3 million |
| Net Loss | $(13.2) million | $(145.2) million |
| Operating Income (Loss) | $47.9 million | $(114.9) million |
| Research & Development Expense | $136.0 million | $163.8 million |
| General & Administrative Expense | $50.7 million | $42.4 million |
| Cash, Cash Equivalents & Investments | $311.6 million | $420.8 million |
| Liability for Sale of Future Royalties | $276.5 million | $353.4 million |
| Accumulated Deficit | $(772.6) million | $(759.3) million |
Note: The company reported a significant reduction in net loss driven by increased collaboration revenue and a decrease in R&D expenses, despite high non-cash interest expense related to royalty monetization.
Material Changes vs. Prior Period
- Revenue Surge: Collaboration revenue increased by $143.3 million (157%) year-over-year. This was driven by:
- GSK Milestones: Recognition of $125.0 million in milestones (including a $75.0 million cash milestone) as Jemperli sales exceeded thresholds.
- Royalties: Increased royalty revenue from Jemperli and Zejula due to sales growth (Jemperli sales reached $1.1 billion in 2025).
- Vanda Deal: $9.7 million in license and transition services revenue from the new imsidolimab agreement.
- R&D Efficiency: R&D expenses decreased by $27.8 million, primarily due to a $21.6 million reduction in clinical expenses and a $12.0 million decrease in manufacturing costs, partially offset by higher personnel costs.
- Non-Cash Interest: Non-cash interest expense for the sale of future royalties increased to $79.9 million (from $50.1 million) due to accelerated royalty payments to Sagard resulting from higher Jemperli sales.
- Stock Repurchases: The company repurchased 3.4 million shares for $68.6 million in 2025 under an expanded $175.0 million authorization.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Separation Plan: The company intends to complete the separation into a Royalty Management Co. and a Biopharma Co. in Q2 2026. The Biopharma entity is expected to launch with capital sufficient for at least 12 months of operations.
- Liquidity: Management believes existing cash and investments ($311.6 million) will fund operations for at least the next 12 months.
- Pipeline Progress:
- Rosnilimab: Phase 2b data in rheumatoid arthritis (RA) met primary and secondary endpoints. The company is assessing advancement to Phase 3.
- ANB033: Phase 1b trials ongoing for celiac disease and eosinophilic esophagitis.
- ANB101: Phase 1 trial initiated in healthy volunteers.
Risks and Contingencies
- Legal Proceedings: AnaptysBio is engaged in litigation with Tesaro/GSK regarding the Collaboration Agreement. AnaptysBio filed a complaint alleging material breach and tortious interference; Tesaro filed a counter-suit. The outcome could materially impact rights and financial position.
- Royalty Monetization: A significant portion of future Jemperli royalties is sold to Sagard. The company retains rights only after Sagard receives $600.0 million (or $675.0 million if after March 2031).
- Development Risks: As a clinical-stage company, there is no guarantee that product candidates will receive regulatory approval or achieve commercial success.
- Section 382 Limitations: Significant federal NOLs ($169.4 million) are subject to annual limitations due to prior ownership changes.
Investor Verification Checklist
- Separation Timeline: Verify the progress of the proposed spin-off and the capitalization plan for the new Biopharma entity.
- Legal Status: Monitor the status of the Delaware Chancery Court litigation with Tesaro/GSK and potential impacts on the Jemperli royalty stream.
- Rosnilimab Phase 3: Confirm the decision and timeline for advancing rosnilimab to Phase 3 trials following the successful Phase 2b data.
- Royalty Thresholds: Track Jemperli sales to determine when the Sagard monetization threshold ($600M/$675M) will be met, allowing AnaptysBio to regain full royalty rights.
- Cash Burn: Assess the run-rate of the Biopharma segment specifically, as the Royalty Management segment is cash-flow positive but monetized.